Search

Your search keyword '"Li, Dai-Yang"' showing total 22 results
Start Over Author "Li, Dai-Yang"
22 results on '"Li, Dai-Yang"'

11. Distribution of killer cell immunoglobulin-like receptor (KIR) genes in a large, multi-centre cohort of Chinese donors

Author

He, Min, primary, Zheng, Zhong-zheng, additional, He, Qing-qing, additional, Li, Dai-yang, additional, Liao, Kuan-zhen, additional, An, Lin, additional, Weng, Qi, additional, Wang, Ning-juan, additional, Wang, Li-ping, additional, Sun, Qin, additional, Wang, Jian, additional, Xiao, Pei-li, additional, Du, Ke-ming, additional, and Jiang, Ming, additional

Published
2021
Full Text
View/download PDF

14. The authors reply

Author

Li, Dai-yang, primary, Yin, Wen-jun, additional, Yi, Yi-hu, additional, Zhang, Bi-kui, additional, Zhao, Jun, additional, Zhu, Chao-nan, additional, Ma, Rong-rong, additional, Zhou, Ling-yun, additional, Xie, Yue-liang, additional, Wang, Jiang-lin, additional, Zuo, Shan-ru, additional, Liu, Kun, additional, Hu, Can, additional, Zhou, Ge, additional, and Zuo, Xiao-cong, additional

Published
2019
Full Text
View/download PDF

15. Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population

Author

Li, Dai-yang, primary, Yin, Wen-jun, additional, Yi, Yi-hu, additional, Zhang, Bi-kui, additional, Zhao, Jun, additional, Zhu, Chao-nan, additional, Ma, Rong-rong, additional, Zhou, Ling-yun, additional, Xie, Yue-liang, additional, Wang, Jiang-lin, additional, Zuo, Shan-ru, additional, Liu, Kun, additional, Hu, Can, additional, Zhou, Ge, additional, and Zuo, Xiao-cong, additional

Published
2019
Full Text
View/download PDF

20. Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients.

Author

Guan, Xiao-feng, Li, Dai-yang, Yin, Wen-jun, Ding, Jun-jie, Zhou, Ling-yun, Wang, Jiang-lin, Ma, Rong-Rong, and Zuo, Xiao-cong

Abstract

Background and Objectives: Diltiazem is a benzothiazepine calcium blocker and widely used in renal transplant patients since it improves the level of tacrolimus or cyclosporine A concentration. Several population pharmacokinetic (PopPK) models had been established for cyclosporine A and tacrolimus but no specific PopPK model was established for diltiazem. The aim of the study is to develop a PopPK model for diltiazem in renal transplant recipients and provide relevant pharmacokinetic parameters of diltiazem for further pharmacokinetic interaction study.Methods: Patients received tacrolimus as primary immunosuppressant agent after renal transplant and started administration of diltiazem 90 mg twice daily on 5th day. The concentration of diltiazem at 0, 0.5, 1, 2, 8, and 12 h was measured by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS). Genotyping for CYP3A4*1G, CYP3A5*3, and MDR1 3435 was conducted by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). 25 covariates were considered in the stepwise covariate model (SCM) building procedure.Results: One-compartment structural pharmacokinetic model with first-order absorption and elimination was used to describe the pharmacokinetic characteristics of diltiazem. Total bilirubin (TBIL) influenced apparent volume of distribution (V/F) of diltiazem in the forward selection. The absorption rate constant (Ka), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.Conclusion: A PopPK model of diltiazem is established in Chinese renal transplant recipients and it will provide relevant pharmacokinetic parameters of diltiazem for further pharmacokinetic interaction study. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

22. [Detection of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia by Novel Digital PCR].

Author

Ruan M, Zhang LL, Li YM, Li DY, Yuan ZY, Zheng ZZ, and Zeng QS

Subjects
Humans, Fusion Proteins, bcr-abl genetics, Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Drug-Related Side Effects and Adverse Reactions
Abstract

Objective: To establish a new digital polymerase chain reaction (dPCR) system for the detection of BCR-ABL fusion gene in patients with chronic myeloid leukemia (CML), and explore its analytical performance and clinical applicability in the detection of BCR-ABL p190/210/230 ., Methods: A new dPCR system for detecting BCR-ABL p190/210/230 was successfully developed, and its sensitivity difference with qPCR and improvement of drug side effects in patients with CML during drug reduction or withdrawal were compared., Results: Among 176 samples, qPCR and dPCR showed high consistency in the sensitivity of detecting BCR-ABL (82.39%), and the positive rate of dPCR was about 5 times higher that of qPCR (20.45% vs 3.98%). During follow-up, blood routine (25% vs 10%), kidney/liver/stomach (25% vs 20%) and cardiac function (10% vs 0) were significantly improved after drug reduction or withdrawal in patients with initial dPCR negative compared with before drug reduction or withdrawal., Conclusions: This new dPCR detection system can be applied to the detection of BCR-ABL p190/210/230 . It has better consistency and higher positive detection rate than qPCR. Drug withdrawal or dose reduction guided by dPCR has a certain effect on improving drug side effects.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results